Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet. This is ...

The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard ...

The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...

A clinical trial has found that low-dose interleukin-2 is safe and may significantly extend survival in people with motor ...

ALS (also known as Motor Neuron Disease (MND)) affects around 45,000 people in Europe at any one time. It attacks the nerves ...

A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.

Results of the landmark MIROCALS clinical trial, published in The Lancet, show a low-dose interleukin-2 (IL2LD) is safe, ...

Results of the landmark MIROCALS clinical trial, involving researchers from the University of Sheffield, have revealed new ...

Parkinson's disease (PD) is a disabling neurodegenerative disease that affects approximately 10 million people worldwide, ...

BioRestorative Therapies is a regenerative medicine company that wants to alleviate chronic lower back pain, obesity and diabetes and is developing stem cell therapies to meet that end.

Motor neurons project from the central nervous system to innervate muscle cells to either directly or indirectly control their activity. Contact between a motor neuron and muscle cell is usually ...